SG11201909265QA - Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to - Google Patents

Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to

Info

Publication number
SG11201909265QA
SG11201909265QA SG11201909265QA SG11201909265QA SG 11201909265Q A SG11201909265Q A SG 11201909265QA SG 11201909265Q A SG11201909265Q A SG 11201909265QA SG 11201909265Q A SG11201909265Q A SG 11201909265QA
Authority
SG
Singapore
Prior art keywords
international
piasmodium
seq
fragment
protein according
Prior art date
Application number
Inventor
Antonio Lanzavecchia
Joshua Hoong Yu Tan
Claudia Daubenberger
Brandon Sack
Original Assignee
Inst Res Biomedicine
Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute
Schweizerisches Tropen Und Public Health Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine, Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute, Schweizerisches Tropen Und Public Health Inst filed Critical Inst Res Biomedicine
Publication of SG11201909265QA publication Critical patent/SG11201909265QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date omit VIII °nolo VIII 11110 101111101111111 (10) International Publication Number WO 2018/193063 A2 25 October 2018 (25.10.2018) WIP0 I PCT (51) International Patent Classification: C07K 16/20 (2006.01) A61K 39/015 (2006.01) Published: A61K 38/03 (2006.01) A61P 33/06 (2006.01) — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (21) International Application Number: — with sequence listing part of description (Rule 5.2(a)) PCT/EP2018/060113 (22) International Filing Date: 19 April 2018 (19.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/487,266 19 April 2017 (19.04.2017) US (71) Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE [CH/CH]; Via Vincenzo Vela 6, 6500 Bellinzona (CH). (72) Inventors: LANZAVECCHIA, Antonio; Via ai Ronchi 6, 6948 Porza (CH). TAN, Joshua Hoong Yu; 4, Jalan Sungai Beranang 32/56, Bukit Rimau, Shah Alam, 40460 (MY). DAUBENBERGER, Claudia; Am Lerchenbuck 17, 79379 Millheim (DE). SACK, Brandon; 1156 Alki Ave SW, Apt 103, Seattle, Washington 98109 (US). (74) Agent: VON STOSCH, Andreas et al.; Prinzregentenstr. 22, 80538 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). O (54) Title: NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO PLASMODIUM SPOROZOITES (57) : The present invention provides a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1, for 00 example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of piasmodium circum- sporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1. The O antibodies according to the present invention bind specifically to P. falciparum sporozoites and may be used in the treatment and/or C prevention of malaria.
SG11201909265Q 2017-04-19 2018-04-19 Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to SG11201909265QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487266P 2017-04-19 2017-04-19
PCT/EP2018/060113 WO2018193063A2 (en) 2017-04-19 2018-04-19 Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Publications (1)

Publication Number Publication Date
SG11201909265QA true SG11201909265QA (en) 2019-11-28

Family

ID=62063036

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909265Q SG11201909265QA (en) 2017-04-19 2018-04-19 Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to

Country Status (14)

Country Link
US (1) US12383609B2 (en)
EP (1) EP3612562A2 (en)
JP (2) JP7278259B2 (en)
KR (1) KR102595238B1 (en)
CN (2) CN110945022B (en)
AU (1) AU2018253918B2 (en)
BR (1) BR112019021824A2 (en)
CA (1) CA3058979A1 (en)
EA (1) EA201992434A1 (en)
IL (1) IL269904B2 (en)
NZ (1) NZ757882A (en)
SG (1) SG11201909265QA (en)
UA (1) UA129243C2 (en)
WO (1) WO2018193063A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110168093B (en) * 2017-09-12 2023-08-15 中科蓝华(广州)生物医药技术有限公司 A kit for transfecting intracellular parasites and its application
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
KR20210018205A (en) 2018-04-03 2021-02-17 사노피 Antigenic OspA polypeptide
WO2019195314A2 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
JP7614841B2 (en) 2018-04-03 2025-01-16 サノフイ Antigenic respiratory syncytial virus polypeptides
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
EP3994166A1 (en) * 2019-07-01 2022-05-11 Deutsches Krebsforschungszentrum Plasmodium antibodies
WO2021016509A1 (en) * 2019-07-24 2021-01-28 Unm Rainforest Innovations Malaria immunogen and methods for using same
EP4041776A4 (en) * 2019-10-09 2025-04-23 The Hospital for Sick Children IMMUNOGENIC PEPTIDES, COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING MALARIA
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
AU2021322831A1 (en) * 2020-08-06 2023-03-09 Macfarlane Burnet Institute For Medical Research And Public Health Limited Immunogenic compositions
US12121574B2 (en) 2021-09-28 2024-10-22 Unm Rainforest Innovations Malaria immunogen and methods for using same
CA3248183A1 (en) 2022-04-14 2023-10-19 The Hospital For Sick Children Pfcsp-based immunogens and related composition and methods
AU2024214379A1 (en) * 2023-02-03 2025-08-21 Atreca, Inc. Anti-csp antibody variants
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12258396B1 (en) * 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US20030119733A1 (en) * 1992-09-17 2003-06-26 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
PL181241B1 (en) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Glucosoamine disaccharides, method of obtaining them and pharmaceutical composition containing them as well as their application
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6207242B1 (en) 1995-12-28 2001-03-27 Hoffman Environmental System, Inc. Laminated package with enhanced interior and exterior
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
CN1168702C (en) 1998-06-30 2004-09-29 Om药业 Acyl-dipeptide compound, its preparation method and pharmaceutical composition containing the aforementioned compound
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
EP1455700A4 (en) 2001-11-16 2007-02-14 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor pathways
JP2006517974A (en) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Methods and compositions for IRM compounds and Toll-like receptor 8
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US7078821B2 (en) 2003-08-27 2006-07-18 Texas Instruments Incorporated Ball film for integrated circuit fabrication and testing
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AP2008004448A0 (en) 2005-09-30 2008-04-30 Seattle Biomedical Res Inst Plasmodium liver stage antigens
CN101190946A (en) * 2006-12-01 2008-06-04 中国人民解放军第二军医大学 Recombinant plasmodium falciparum circumsporozoite surface protein and its preparing process and application
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR100968848B1 (en) 2007-12-13 2010-07-09 주식회사 바이오랜드 Antibodies specific to trifluid and febrile malaria lactate dehydrogenases and diagnostic kits for overlapping infection of tropical malaria and trifluid malaria comprising the same
CN101977932B (en) 2008-01-31 2014-09-03 美国政府健康及人类服务部 Engineered antibody constant domain molecules
PL2350128T3 (en) 2008-10-22 2015-03-31 Inst Res Biomedicine Methods for producing antibodies from plasma cells
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
AU2011313913A1 (en) * 2010-10-10 2013-05-02 Aduro Biotech Methods and compositions for inducing a T-cell response to Plasmodium species
BR112013023918A2 (en) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa hetero-dimeric immunoglobulin or hetero-dimeric fragment thereof, method for producing a hetero-dimeric immunoglobulin or hetero-dimeric fragment thereof, method for constructing a protein-protein interface of a domain of a multi-domain protein and use of a domain donor of a first and second member of a naturally occurring immunoglobulin superfamily
TWI743461B (en) 2011-03-28 2021-10-21 法商賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
EP2825557B1 (en) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
WO2014028644A1 (en) * 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
SG10201709917VA (en) 2013-06-03 2017-12-28 Vlp Therapeutics Llc Malaria vaccine
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
WO2017163049A1 (en) * 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US11066464B2 (en) * 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES

Also Published As

Publication number Publication date
IL269904B2 (en) 2025-10-01
CN110945022B (en) 2024-04-05
JP2023058633A (en) 2023-04-25
BR112019021824A2 (en) 2020-06-02
CA3058979A1 (en) 2018-10-25
US20200093909A1 (en) 2020-03-26
EA201992434A1 (en) 2020-03-30
AU2018253918A1 (en) 2019-10-31
AU2018253918B2 (en) 2025-04-03
CN110945022A (en) 2020-03-31
EP3612562A2 (en) 2020-02-26
KR20200141917A (en) 2020-12-21
UA129243C2 (en) 2025-02-26
US12383609B2 (en) 2025-08-12
JP2020520674A (en) 2020-07-16
KR102595238B1 (en) 2023-10-26
NZ757882A (en) 2025-11-28
WO2018193063A3 (en) 2019-01-03
JP7278259B2 (en) 2023-05-19
IL269904A (en) 2019-11-28
CN118085055A (en) 2024-05-28
IL269904B1 (en) 2025-06-01
WO2018193063A2 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
SG11201909265QA (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201808709VA (en) T cell receptors
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201909353VA (en) Hbv vaccine
SG11201807912SA (en) Vaccine against rsv
SG11201901790YA (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
SG11201900482SA (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201806340YA (en) Zika virus vaccine
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201808751SA (en) T cell receptors
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201811442UA (en) Formulation of a peptide vaccine